相关实验视频
Updated: Jun 29, 2025

04:23
Application of Hemostatic Devices in Laparoscopic Hepatectomy
Published on: April 19, 2022
2.2K
在接受心脏手术的患者中使用前列红素复合度的血静:系统性审查与元分析
Jun-Ping Li1, Yan Li2, Bing Li3
1Medical Oncology, Zibo Municipal Hospital, Zibo, Shandong, People's Republic of China.
Brazilian journal of cardiovascular surgery
|April 3, 2024
概括
在心脏外科手术中使用前列红素复合缩剂 (PCC) 并没有增加死亡率或住院时间. 然而,PCC显著减少了术后重症监护室停留,出血和需要机械循环支持的需要.
科学领域:
- 心脏病学 心脏病学
- 麻醉学 麻醉学
- 关键护理医学 关键护理医学
背景情况:
- 大量出血是心脏手术中的重要并发症.
- 血栓复合缩剂 (PCC) 用于控制出血,但其在心脏手术患者的疗效和安全性需要全面评估.
研究的目的:
- 综合探索前红素复合缩剂 (PCC) 在接受心脏手术的患者治疗大量出血的疗效和安全性.
主要方法:
- 进行了一项元分析,搜索PubMed,Embase和Cochrane图书馆,查找2022年9月10日之前发表的相关研究.
- 连续数据使用 95% 置信区间 (CI) 的平均差异 (MD) 进行分析,并使用 95% CI 的风险比率 (RR) 分析二分法数据.
主要成果:
- 包括12项研究. 与非PCC治疗方案相比,PCC与死亡率增加,住院时间缩短,胸腔排水减少或血栓栓塞事件,心房动或心肌梗塞的更高率无关.
- 然而,PCC使用与集中护理病房停留时间缩短 (MD=-0.81天,P=0.02),出血减少 (MD=-248.67毫升,P=0.02),以及动脉内气球/体外膜氧化使用率较低 (RR=0.65,P=0.05).
结论:
- 在心脏外科手术患者中,胺复合缩剂 (PCC) 的使用与增加的死亡率,住院,胸腔排水或特定不良事件 (如心房动,心肌梗塞或血栓栓事件) 无关.
- PCC显著改善了手术后的结果,包括减少了重症监护室的停留时间,减少了血液流失,减少了对机械循环支持的需求 (大动脉内气球/体外膜氧化).
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
690
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
690
Extrinsic and Intrinsic Pathways of Hemostasis
7.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.5K
Introduction to Hemostasis
7.6K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.6K
Coagulation
6.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.5K

